Aliases & Classifications for Social Phobia

MalaCards integrated aliases for Social Phobia:

Name: Social Phobia 12 14
Phobic Anxiety Disorder 69
Phobic Disorders 42
Phobia, Social 69
Phobia Social 52

Classifications:



External Ids:

Disease Ontology 12 DOID:11257
ICD9CM 35 300.23
MeSH 42 D010698
NCIt 47 C34927
UMLS 69 C0031572

Summaries for Social Phobia

Disease Ontology : 12 A phobic disorder that involves social anxiety occurring only in specific public or social situations, interactions with others or being evaluated or scrutinized by other people.

MalaCards based summary : Social Phobia, also known as phobic anxiety disorder, is related to strabismus and personality disorder. An important gene associated with Social Phobia is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Norepinephrine and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and amygdala, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Related Diseases for Social Phobia

Diseases related to Social Phobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
id Related Disease Score Top Affiliating Genes
1 strabismus 29.9 DRD2 PRL
2 personality disorder 29.3 CCK DRD2 MAOA SLC6A4
3 sexual disorder 28.9 DRD2 MAOA SLC6A4
4 schizophrenia 27.3 CCK DRD2 HTR3A MAOA PRL SLC6A4
5 phobic disorder 12.1
6 anxiety disorder 10.5
7 avoidant personality disorder 10.5
8 conjunctival pigmentation 10.5 MAOA SLC6A4
9 panic disorder 10.4
10 uterus intravascular leiomyomatosis 10.4 MAOA SLC6A4
11 neurogenic bladder 10.4 MAOA SLC6A4
12 tinea pedis 10.4 MAOA SLC6A4
13 aphasia 10.3 MAOA PRL
14 agoraphobia 10.3
15 hydromyelia 10.3 PRL SOD1
16 angiokeratoma of mibelli 10.3 MAOA SLC6A4
17 intrahepatic gall duct cancer 10.3 MAOA SLC6A4
18 generalized anxiety disorder 10.3
19 luxation of globe 10.3 PRL SLC6A4
20 obsessive-compulsive personality disorder 10.3 MAOA SLC6A4
21 anodontia 10.3 HTR3A SLC6A4
22 47,xyy syndrome 10.2 PRL SOD1
23 dyspepsia 10.2 CCK PRL
24 obsessive-compulsive disorder 10.2
25 keratosis 10.2 MAOA SLC6A4
26 hypoglycemic coma 10.2 MAOA SLC6A4
27 perianal hematoma 10.1 CCK SOD1
28 mutism 10.1
29 chronic dacryoadenitis 10.1 MAOA PRL SLC6A4
30 scleral staphyloma 10.1 CCK HTR3A
31 rhinoscleroma 10.0 DRD2 PRL
32 water-clear cell adenoma 10.0 DRD2 PRL
33 peroxisomal biogenesis disorders 10.0 DRD2 PRL
34 intracranial cavernous angioma 10.0 DRD2 SLC6A4
35 renpenning syndrome 10.0 HTR3A MAOA SLC6A4
36 splenic abscess 10.0 DRD2 SLC6A4
37 acquired aneurysmal subarachnoid hemorrhage 10.0 HTR3A MAOA SLC6A4
38 hyperthyroxinemia 10.0 DRD2 SLC6A4
39 phobia, specific 9.9
40 body dysmorphic disorder 9.9
41 separation anxiety disorder 9.9
42 pompholyx 9.9 DRD2 SLC6A4
43 anosognosia 9.9 DRD2 SLC6A4
44 vallecula cancer 9.9 MAOA SLC6A4
45 autoimmune-related retinopathy and optic neuropathy 9.9 HTR3A PRL SLC6A4
46 atrial fibrillation, familial, 10 9.9 HTR3A MAOA SLC6A4
47 cold-induced sweating syndrome 2 9.9 DRD2 PRL
48 elective mutism 9.9
49 acne 9.9
50 mood disorder 9.9

Comorbidity relations with Social Phobia via Phenotypic Disease Network (PDN):


Anxiety Disorder Dysthymic Disorder

Graphical network of the top 20 diseases related to Social Phobia:



Diseases related to Social Phobia

Symptoms & Phenotypes for Social Phobia

MGI Mouse Phenotypes related to Social Phobia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.87 CCK DRD2 HTR3A MAOA PRL SLC6A4
2 endocrine/exocrine gland MP:0005379 9.73 CCK DRD2 HTR3A PRL SLC6A4 SOD1
3 homeostasis/metabolism MP:0005376 9.7 HTR3A MAOA PRL SLC6A4 SOD1 CCK
4 integument MP:0010771 9.35 DRD2 HTR3A PRL SLC6A4 SOD1
5 nervous system MP:0003631 9.17 CCK DRD2 HTR3A MAOA PRL SLC6A4

Drugs & Therapeutics for Social Phobia

Drugs for Social Phobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
2
Citalopram Approved Phase 4,Phase 2,Phase 1 59729-33-8 2771
3
Ethanol Approved Phase 4,Phase 2 64-17-5 702
4
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
5
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
6
Cycloserine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68-41-7 401 6234
7
Tiagabine Approved Phase 4 115103-54-3 60648
8
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
9
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
10
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
11 Piracetam Approved Phase 4,Phase 2 7491-74-9
12
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
13
Propranolol Approved, Investigational Phase 4,Phase 2 525-66-6 4946
14
Topiramate Approved Phase 4 97240-79-4 5284627
15
Acetylcholine Approved Phase 4 51-84-3 187
16
Ketamine Approved, Vet_approved Phase 4,Early Phase 1 6740-88-1 3821
17
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
18
Vortioxetine Approved Phase 4 508233-74-7 9966051
19
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
20
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
21 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
22 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
29 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Cholinergic Agents Phase 4,Phase 2,Phase 1
35 Cholinergic Antagonists Phase 4,Phase 2,Phase 1
36 Muscarinic Antagonists Phase 4,Phase 2,Phase 1
37 Parasympatholytics Phase 4,Phase 2,Phase 1
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Serotonin 5-HT1 Receptor Agonists Phase 4
40 Antipsychotic Agents Phase 4,Phase 2,Phase 3,Early Phase 1
41 Quetiapine Fumarate Phase 4,Phase 2,Phase 3,Early Phase 1 111974-72-2
42 Tranquilizing Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Anticonvulsants Phase 4,Phase 2,Phase 3
44 GABA Agents Phase 4,Phase 1
45 GABA Modulators Phase 4,Phase 1
46 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3
47 Venlafaxine Hydrochloride Phase 4,Phase 3
48 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 251)

id Name Status NCT ID Phase Drugs
1 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
2 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
3 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
4 Nefazodone in the Treatment of Social Phobia Completed NCT00231348 Phase 4 Nefazodone
5 Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder Completed NCT00208741 Phase 4 Gabitril
6 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Completed NCT01316302 Phase 4 Pristiq;Placebo
7 Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder Completed NCT00872131 Phase 4 Sertraline
8 Escitalopram in Patients With Social Anxiety Disorder Completed NCT00902226 Phase 4 Escitalopram
9 Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
10 Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4 Atomoxetine hydrochloride;placebo
11 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
12 RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
13 Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents Completed NCT01160588 Phase 4 Sertraline
14 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
15 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
16 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
17 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
18 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
19 Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP) Recruiting NCT00182455 Phase 4 Topiramate;Placebo
20 A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder Recruiting NCT03078270 Phase 4 botulinum toxin A
21 Brief Intervention to Reduce Fear of Public Speaking Recruiting NCT02790736 Phase 4 propranolol;placebo
22 Ketamine Infusion for Adolescent Depression and Anxiety Recruiting NCT02579928 Phase 4 Ketamine;Midazolam
23 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
24 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Active, not recruiting NCT02294305 Phase 4 Vortioxetine;Placebo
25 Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias Terminated NCT01623583 Phase 4
26 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Unknown status NCT01388231 Phase 2, Phase 3
27 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
28 Residential Cognitive and Interpersonal Therapy for Social Phobia Completed NCT00326430 Phase 2, Phase 3
29 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
30 A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy Completed NCT00564967 Phase 3
31 Quetiapine in Social Anxiety Disorder Completed NCT00215254 Phase 2, Phase 3 quetiapine
32 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia Completed NCT00515879 Phase 3 D-cycloserine;Placebo
33 Social Anxiety Disorder Study Of Paroxetine Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
34 Flushing in Social Anxiety Disorder on Seroquel Completed NCT00773162 Phase 3 Seroquel;Sugar Pill
35 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder Completed NCT00074802 Phase 3 Paroxetine
36 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder Completed NCT00260533 Phase 2, Phase 3 atomoxetine;placebo
37 Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) Completed NCT02622958 Phase 3 PH94B
38 Long-term Study Of Paroxetine in Women and Men Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
39 Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder Completed NCT00238719 Phase 3 Venlafaxine ER
40 Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Completed NCT00958880 Phase 3 Yohimbine Hydrochloride;Sugar Pill
41 St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD) Completed NCT00118833 Phase 2, Phase 3 Hypericum perforatum (St. John's wort)
42 Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome Completed NCT00114127 Phase 3 Duloxetine;Duloxetine;Placebo
43 A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder Completed NCT01654510 Phase 2, Phase 3
44 A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder Completed NCT00411398 Phase 3 Namenda/Memantine
45 Treatment for Anxiety in Children Completed NCT00000389 Phase 3 Fluvoxamine
46 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
47 Child and Adolescent Anxiety Disorders (CAMS) Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
48 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed NCT01178385 Phase 2, Phase 3
49 Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder Recruiting NCT03017508 Phase 2, Phase 3 BHV-0223;Placebo
50 Psychotherapy for Anxiety in Children With Autism Spectrum Disorder Recruiting NCT02028247 Phase 3

Search NIH Clinical Center for Social Phobia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: phobic disorders

Genetic Tests for Social Phobia

Anatomical Context for Social Phobia

MalaCards organs/tissues related to Social Phobia:

39
Brain, Testes, Amygdala, Heart, Cortex, Pituitary, Hypothalamus

Publications for Social Phobia

Articles related to Social Phobia:

(show top 50) (show all 610)
id Title Authors Year
1
Comorbidity of schizophrenia and social phobia - impact on quality of life, hope, and personality traits: a cross sectional study. ( 28831256 )
2017
2
Confirmatory Factor Analysis of the Combined Social Phobia Scale and Social Interaction Anxiety Scale: Support for a Bifactor Model. ( 28210232 )
2017
3
Collaborative care for panic disorder, generalised anxiety disorder and social phobia in general practice: study protocol for three cluster-randomised, superiority trials. ( 28814317 )
2017
4
Identifying sub-categories of social fears using an alternative factor analytic structure of the Social Phobia and Anxiety Inventory. ( 28236783 )
2017
5
Depression and social phobia in essential tremor and Parkinson's disease. ( 28948077 )
2017
6
Daily fluctuation of emotions and memories thereof: Design and methods of an experience sampling study of major depression, social phobia, and controls. ( 28948700 )
2017
7
Social phobia, depression and eating disorders during middle adolescence: longitudinal associations and treatment seeking. ( 28868945 )
2017
8
Hypochondriasis Differs From Panic Disorder and Social Phobia: Specific Processes Identified Within Patient Groups. ( 27805984 )
2016
9
Community-Based Validation of the Social Phobia Screener (SOPHS). ( 26939801 )
2016
10
Psychometric properties of the mini-social phobia inventory (Mini-SPIN) in a large online treatment-seeking sample. ( 27046641 )
2016
11
Social Phobia Is Associated with Delayed Onset of Chickenpox, Measles, and Mumps Infections. ( 28082921 )
2016
12
Selective Mutism: The Fraternal Twin of Childhood Social Phobia. ( 27089281 )
2016
13
Retracted: Combined Case of Blood-Injury-Injection Phobia and Social Phobia: Behavior Therapy Management and Effectiveness through Tilt Test. ( 27722005 )
2016
14
Autonomic markers associated with generalized social phobia symptoms: heart rate variability and salivary alpha-amylase. ( 27892761 )
2016
15
Virtual reality exposure using three-dimensional images for the treatment of social phobia. ( 26561376 )
2016
16
Social Phobia: The Role of In-Situation Safety Behaviors in Maintaining Anxiety and Negative Beliefs - Republished Article. ( 27816079 )
2016
17
Assimilation, reflexivity, and therapist responsiveness in group psychotherapy for social phobia: A case study. ( 27092848 )
2016
18
No effects of psychosocial stress on memory retrieval in non-treated young students with Generalized Social Phobia. ( 27464065 )
2016
19
Factor solutions of the Social Phobia Scale (SPS) and the Social Interaction Anxiety Scale (SIAS) in a Swedish population. ( 27894213 )
2016
20
The effect of Interaction Anxiousness Scale and Brief Social Phobia Scale for screening social anxiety disorder in college students: a study on discriminative validity. ( 27935389 )
2016
21
Examination of the Correlation Between Internet Addiction and Social Phobia in Adolescents. ( 27561297 )
2016
22
Attentional mechanisms of social perception are biased in social phobia. ( 27131909 )
2016
23
Developmental Differences in Functioning in Youth With Social Phobia. ( 26630122 )
2015
24
An experimental investigation of the functional relationship between social phobia and cigarette smoking. ( 25576952 )
2015
25
Social anxiety disorders in clinical practice: differentiating social phobia from avoidant personality disorder. ( 26129819 )
2015
26
Short-term Dynamic Psychotherapy versus Sertraline in Treatment of Social Phobia. ( 26288643 )
2015
27
Latent dimensions of social anxiety disorder: A re-evaluation of the Social Phobia Inventory (SPIN). ( 26454660 )
2015
28
Correction: The Neuroanatomical Basis of Panic Disorder and Social Phobia in Schizophrenia: A Voxel Based Morphometric Study. ( 25906143 )
2015
29
Social phobia and quality of life in morbidly obese patients before and after bariatric surgery. ( 25863007 )
2015
30
The neuroanatomical basis of panic disorder and social phobia in schizophrenia: a voxel based morphometric study. ( 25774979 )
2015
31
Correction: Avoidant Personality Disorder versus Social Phobia: The Significance of Childhood Neglect. ( 25978045 )
2015
32
Social Phobia and Educational and Interpersonal Impairments in Adolescence: A Prospective Study. ( 26514560 )
2015
33
Intensive Group-Based CBT for Child Social Phobia: A Pilot Study. ( 25892171 )
2015
34
Comparison of automatical thoughts among generalized anxiety disorder, major depressive disorder and generalized social phobia patients. ( 26241548 )
2015
35
Behavioral treatment of social phobia in youth: Does parent education training improve the outcome? ( 25727679 )
2015
36
Reprint of: Social phobia and other psychiatric problems in children with strabismus. ( 26049893 )
2015
37
Avoidant Personality Disorder versus Social Phobia: The Significance of Childhood Neglect. ( 25815817 )
2015
38
Attachment styles in patients with avoidant personality disorder compared with social phobia. ( 26332087 )
2015
39
Social Phobia symptoms across the adult lifespan. ( 25043319 )
2014
40
Baseline Patient Characteristics Predicting Outcome and Attrition in Cognitive Therapy for Social Phobia: Results from a Large Multicentre Trial. ( 25504802 )
2014
41
Clinical experiences in conducting cognitive-behavioral therapy for social phobia. ( 24411111 )
2014
42
Comparison of attention training and cognitive therapy in the treatment of social phobia: a preliminary investigation. ( 23228587 )
2014
43
Have we met before? Neural correlates of emotional learning in women with social phobia. ( 24758944 )
2014
44
Randomized Controlled Trial of Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for Social Phobia: Outcomes and Moderators. ( 24999670 )
2014
45
Associations between body weight and depression, social phobia, insomnia, and self-esteem among Taiwanese adolescents. ( 25476101 )
2014
46
Biased attention to threat in paediatric anxiety disorders (generalized anxiety disorder, social phobia, specific phobia, separation anxiety disorder) as a function of 'distress' versus 'fear' diagnostic categorization. ( 23591000 )
2014
47
The contribution of the therapist's competence in the treatment of adolescents with generalized social phobia. ( 25340895 )
2014
48
Social phobia in Parkinson's disease: Prevalence and risk factors. ( 24926195 )
2014
49
Hypnosis aided fixed role therapy for social phobia: a case report. ( 24938079 )
2014
50
Comparing Short Forms of the Social Interaction Anxiety Scale and the Social Phobia Scale. ( 24932648 )
2014

Variations for Social Phobia

Expression for Social Phobia

Search GEO for disease gene expression data for Social Phobia.

Pathways for Social Phobia

GO Terms for Social Phobia

Cellular components related to Social Phobia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.13 CCK HTR3A SOD1
2 axon GO:0030424 8.8 CCK DRD2 HTR3A

Biological processes related to Social Phobia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.54 DRD2 SLC6A4 SOD1
2 response to cocaine GO:0042220 9.32 DRD2 HTR3A
3 response to axon injury GO:0048678 9.26 DRD2 SOD1
4 regulation of multicellular organism growth GO:0040014 9.16 PRL SOD1
5 response to amphetamine GO:0001975 8.96 DRD2 SOD1
6 response to ethanol GO:0045471 8.8 DRD2 HTR3A SOD1

Sources for Social Phobia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....